Please check your internet connection and try again.
```markdown
# Durveqtix Gene Therapy
## Overview
Durveqtix (prademagenovemur) is a one-time gene therapy for the treatment of hemophilia A. It delivers a functional copy of the Factor VIII (FVIII) gene to liver cells, enabling the body to produce its own FVIII.
## Primary Indications
Durveqtix is indicated for the treatment of hemophilia A in adult and pediatric patients aged 12 years and older who have severe, Factor VIII deficient hemophilia A (congenital FVIII deficiency without FVIII inhibitors).
## Adult Dosing
The recommended dose of Durveqtix is **1.25 x 10^13 vector genomes per kilogram (vg/kg)** administered as a single intravenous infusion.
## Pediatric Dosing
The recommended dose of Durveqtix is **1.25 x 10^13 vector genomes per kilogram (vg/kg)** administered as a single intravenous infusion for patients aged 12 years and older. Dosing for pediatric patients under 12 years of age has not been established.
## Dose Adjustments
No dose adjustments are necessary based on age (within the approved age range), sex, or body weight.
## Contraindications
* Hypersensitivity to the active substance or any excipients.
* Patients who have developed a serious immune response to a previous dose of Durveqtix.
## Adverse Effects
The most common adverse reactions observed in clinical trials include:
* Infusion-related reactions (e.g., headache, fever, nausea, vomiting, chills, fatigue)
* Elevated liver enzymes (ALT, AST)
* Headache
* Abdominal pain
* Dizziness
* Rash
* Increased blood creatinine phosphokinase
Serious adverse reactions may include immune responses to the transgene product (Factor VIII) or the adeno-associated virus (AAV) vector, and thrombotic events.
## Key Drug Interactions
* **Immunosuppressive therapy:** Concurrent use of immunosuppressants may be required to manage potential immune responses to the AAV vector or transgene product. The need for and type of immunosuppression should be determined by a healthcare professional experienced in gene therapy.
* **Corticosteroids:** Concomitant use of corticosteroids may increase the risk of adverse effects, particularly if used for prolonged periods or at high doses to manage immune responses.
## Monitoring
* **Liver Function Tests:** Monitor ALT, AST, and bilirubin before treatment and at regular intervals for at least 6 months after administration, and as clinically indicated thereafter.
* **Factor VIII activity levels:** Monitor FVIII activity to assess the durability of the response and guide clinical management.
* **Antibody testing:** Monitor for the development of neutralizing antibodies to the AAV vector and FVIII.
* **Immune response monitoring:** Close monitoring for signs and symptoms of immune reactions (e.g., elevated liver enzymes, rash, constitutional symptoms) is crucial.
## Clinical Pearls
* Durveqtix is a one-time infusion.
* Patients should be monitored closely for at least 6 months post-infusion for immune responses and changes in liver function.
* The long-term durability and safety of Durveqtix are still under evaluation.
* Management of immune responses is critical for efficacy and safety. Consult with a gene therapy specialist.
***
**Disclaimer:** This information is intended for clinical pharmacists and healthcare professionals. It is essential to consult the official prescribing information and relevant local guidelines for the most current and complete drug information, including specific details on administration, handling, and patient counseling.
```
